Limitations of non-invasive tests for assessment of liver fibrosis

Keyur Patel, Giada Sebastiani, Keyur Patel, Giada Sebastiani

Abstract

The diagnostic assessment of liver injury is an important step in the management of patients with chronic liver disease (CLD). Although liver biopsy is the reference standard for the assessment of necroinflammation and fibrosis, the inherent limitations of an invasive procedure, and need for repeat sampling, have led to the development of several non-invasive tests (NITs) as alternatives to liver biopsy. Such non-invasive approaches mostly include biological (serum biomarker algorithms) or physical (imaging assessment of tissue stiffness) assessments. However, currently available NITs have several limitations, such as variability, inadequate accuracy and risk factors for error, while the development of a newer generation of biomarkers for fibrosis may be limited by the sampling error inherent to the reference standard. Many of the current NITs were initially developed to diagnose significant fibrosis in chronic hepatitis C, subsequently refined for the diagnosis of advanced fibrosis in patients with non-alcoholic fatty liver disease, and further adapted for prognostication in CLD. An important consideration is that despite their increased use in clinical practice, these NITs were not designed to reflect the dynamic process of fibrogenesis, differentiate between adjacent disease stages, diagnose non-alcoholic steatohepatitis, or follow longitudinal changes in fibrosis or disease activity caused by natural history or therapeutic intervention. Understanding the strengths and limitations of these NITs will allow for more judicious interpretation in the clinical context, where NITs should be viewed as complementary to, rather than as a replacement for, liver biopsy.

Keywords: AGA, American Gastroenterology Association; ALT, alanine aminotransferase; APRI, AST-platelet ratio index; AST, aspartate aminotransferase; AUC, area under the curve; BMI, body mass index; Biomarkers; CAP, controlled attenuation parameter; CHB, chronic hepatitis B; CHC, chronic hepatitis C; CLD, chronic liver disease; CPA, collagen proportionate area; DAA, direct-acting antiviral; ELF, enhanced liver fibrosis; Elastography; FIB-4, fibrosis-4; FLIP, fatty liver inhibition of progression; HCC, hepatocellular carcinoma; IFN, interferon; LSM, liver stiffness measure; Liver biopsy; MR, magnetic resonance; MRE, magnetic resonance elastography; NAFLD, non-alcoholic fatty liver disease; NFS, NAFLD fibrosis score; NITs, non-invasive tests; Non-alcoholic fatty liver disease; SVR, sustained virologic response; US, ultrasound; VCTE, vibration-controlled transient elastography; Viral hepatitis.

Conflict of interest statement

The authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details.

© 2020 The Author(s).

Figures

Fig. 1
Fig. 1
Guidance and consideration in using NIT for staging liver fibrosis. NIT, non-invasive test.
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7047178/bin/fx1.jpg

References

    1. European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–264.
    1. Bedossa P., Paradis V. Liver extracellular matrix in health and disease. J Pathol. 2003;200:504–515.
    1. European Association for the Study of the Liver. European Association for the Study of Diabetes. European Association for the Study of Obesity EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64:1388–1402.
    1. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994;20:15–20.
    1. Brunt E.M., Kleiner D.E., Wilson L.A., Belt P., Neuschwander-Tetri B.A., Network N.C.R. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011;53:810–820.
    1. Mehta S.H., Lau B., Afdhal N.H., Thomas D.L. Exceeding the limits of liver histology markers. J Hepatol. 2009;50:36–41.
    1. Poynard T., Halfon P., Castera L., Charlotte F., Le Bail B., Munteanu M. Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation. Aliment Pharmacol Ther. 2007;25:733–739.
    1. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38:1449–1457.
    1. Rockey D.C., Caldwell S.H., Goodman Z.D., Nelson R.C., Smith A.D. Liver biopsy. Hepatology. 2009;49:1017–1044.
    1. Bravo A.A., Sheth S.G., Chopra S. Liver biopsy. N Engl J Med. 2001;344:495–500.
    1. Cholongitas E., Senzolo M., Standish R., Marelli L., Quaglia A., Patch D. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol. 2006;125:710–721.
    1. Standish R.A., Cholongitas E., Dhillon A., Burroughs A.K., Dhillon A.P. An appraisal of the histopathological assessment of liver fibrosis. Gut. 2006;55:569–578.
    1. Schiano T.D., Azeem S., Bodian C.A., Bodenheimer H.C., Jr., Merati S., Thung S.N. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2005;3:930–935.
    1. Colloredo G., Guido M., Sonzogni A., Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003;39:239–244.
    1. Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology. 2014;60:565–575.
    1. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.
    1. Westin J., Lagging L.M., Wejstal R., Norkrans G., Dhillon A.P. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver. 1999;19:183–187.
    1. Rousselet M.C., Michalak S., Dupre F., Croue A., Bedossa P., Saint-Andre J.P. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology. 2005;41:257–264.
    1. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614–2618.
    1. Karsdal M.A., Manon-Jensen T., Genovese F., Kristensen J.H., Nielsen M.J., Sand J.M. Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2015;308:G807–G830.
    1. Goodman Z.D., Becker R.L., Jr., Pockros P.J., Afdhal N.H. Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis. Hepatology. 2007;45:886–894.
    1. Goodman Z.D., Stoddard A.M., Bonkovsky H.L., Fontana R.J., Ghany M.G., Morgan T.R. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology. 2009;50:1738–1749.
    1. McHutchison J., Goodman Z., Patel K., Makhlouf H., Rodriguez-Torres M., Shiffman M. Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. 2010;138:1365–1373. 1373.e1-2.
    1. Tsochatzis E., Bruno S., Isgro G., Hall A., Theocharidou E., Manousou P. Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. J Hepatol. 2014;60:948–954.
    1. Sandrini J., Boursier J., Chaigneau J., Sturm N., Zarski J.P., Le Bail B. Quantification of portal-bridging fibrosis area more accurately reflects fibrosis stage and liver stiffness than whole fibrosis or perisinusoidal fibrosis areas in chronic hepatitis C. Mod Pathol. 2014;27:1035–1045.
    1. Xu S., Wang Y., Tai D.C., Wang S., Cheng C.L., Peng Q. qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. J Hepatol. 2014;61:260–269.
    1. Gailhouste L., Le Grand Y., Odin C., Guyader D., Turlin B., Ezan F. Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis. J Hepatol. 2010;52:398–406.
    1. Trautwein C., Friedman S.L., Schuppan D., Pinzani M. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62:S15–S24.
    1. Castera L., Forns X., Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48:835–847.
    1. Castera L., Foucher J., Bernard P.H., Carvalho F., Allaix D., Merrouche W. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828–835.
    1. Wong G.L., Wong V.W., Chim A.M., Yiu K.K., Chu S.H., Li M.K. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population. J Gastroenterol Hepatol. 2011;26:300–305.
    1. Boursier J., Zarski J.P., de Ledinghen V., Rousselet M.C., Sturm N., Lebail B. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57:1182–1191.
    1. Das K., Sarkar R., Ahmed S.M., Mridha A.R., Mukherjee P.S., Dhali G.K. “Normal” liver stiffness measure (LSM) values are higher in both lean and obese individuals: a population-based study from a developing country. Hepatology. 2012;55:584–593.
    1. Myers R.P., Pomier-Layrargues G., Kirsch R., Pollett A., Duarte-Rojo A., Wong D. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology. 2012;55:199–208.
    1. Wong V.W., Irles M., Wong G.L., Shili S., Chan A.W., Merrouche W. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut. 2019;68:2057–2064.
    1. Tapper E.B., Castera L., Afdhal N.H. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2015;13:27–36.
    1. Huang R., Gao Z.H., Tang A., Sebastiani G., Deschenes M. Transient elastography is an unreliable marker of liver fibrosis in patients with portal vein thrombosis. Hepatology. 2018;68:783–785.
    1. Tapper E.B., Cohen E.B., Patel K., Bacon B., Gordon S., Lawitz E. Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2012;10(8):932–937.e1.
    1. Arena U., Lupsor Platon M., Stasi C., Moscarella S., Assarat A., Bedogni G. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology. 2013;58:65–72.
    1. Singh S., Muir A.J., Dieterich D.T., Falck-Ytter Y.T. American Gastroenterological Association Institute technical review on the role of elastography in chronic liver diseases. Gastroenterology. 2017;152:1544–1577.
    1. de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752.
    1. Kennedy P., Wagner M., Castera L., Hong C.W., Johnson C.L., Sirlin C.B. Quantitative elastography methods in liver disease: current evidence and future directions. Radiology. 2018;286:738–763.
    1. Tang A., Cloutier G., Szeverenyi N.M., Sirlin C.B. Ultrasound elastography and MR elastography for assessing liver fibrosis: part 1, principles and techniques. AJR Am J Roentgenol. 2015;205:22–32.
    1. Serai S.D., Yin M., Wang H., Ehman R.L., Podberesky D.J. Cross-vendor validation of liver magnetic resonance elastography. Abdom Imaging. 2015;40:789–794.
    1. Wagner M., Corcuera-Solano I., Lo G., Esses S., Liao J., Besa C. Technical failure of MR elastography examinations of the liver: experience from a large single-center study. Radiology. 2017;284:401–412.
    1. Singh S., Venkatesh S.K., Wang Z., Miller F.H., Motosugi U., Low R.N. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015;13:440–451.e6.
    1. Imbert-Bismut F., Ratziu V., Pieroni L., Charlotte F., Benhamou Y., Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357:1069–1075.
    1. Wai C.T., Greenson J.K., Fontana R.J., Kalbfleisch J.D., Marrero J.A., Conjeevaram H.S. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–526.
    1. Patel K., Gordon S.C., Jacobson I., Hezode C., Oh E., Smith K.M. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol. 2004;41:935–942.
    1. Adams L.A., Bulsara M., Rossi E., DeBoer B., Speers D., George J. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867–1873.
    1. Forns X., Ampurdanes S., Llovet J.M., Aponte J., Quinto L., Martinez-Bauer E. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986–992.
    1. Cales P., Oberti F., Michalak S., Hubert-Fouchard I., Rousselet M.C., Konate A. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373–1381.
    1. Rosenberg W.M., Voelker M., Thiel R., Becka M., Burt A., Schuppan D. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127:1704–1713.
    1. Boursier J., de Ledinghen V., Poynard T., Guechot J., Carrat F., Leroy V. An extension of STARD statements for reporting diagnostic accuracy studies on liver fibrosis tests: the Liver-FibroSTARD standards. J Hepatol. 2015;62:807–815.
    1. Guha I.N., Myers R.P., Patel K., Talwalkar J.A. Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve? Hepatology. 2011;54:1454–1462.
    1. Lindqvist U., Laurent T.C. Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age. Scand J Clin Lab Invest. 1992;52:613–621.
    1. Fraser J.R., Gibson P.R. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J Intern Med. 2005;258:460–466.
    1. Parkes J., Guha I.N., Roderick P., Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol. 2006;44:462–474.
    1. Cales P., de Ledinghen V., Halfon P., Bacq Y., Leroy V., Boursier J. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008;28:1352–1362.
    1. Patel K., Remlinger K.S., Walker T.G., Leitner P., Lucas J.E., Gardner S.D. Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12(12) 2113–2120.e1-3.
    1. Chou R., Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med. 2013;159:372.
    1. Chhatwal J., Wang X., Ayer T., Kabiri M., Chung R.T., Hur C. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology. 2016;64:1442–1450.
    1. Gowda C., Lott S., Grigorian M., Carbonari D.M., Saine M.E., Trooskin S. Absolute insurer denial of direct-acting antiviral therapy for hepatitis C: a National Specialty Pharmacy Cohort Study. Open Forum Infect Dis. 2018;5:ofy076.
    1. Lee Y.A., Friedman S.L. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res. 2014;107:23–30.
    1. Poynard T., McHutchison J., Manns M., Trepo C., Lindsay K., Goodman Z. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303–1313.
    1. D'Ambrosio R., Aghemo A., Rumi M.G., Ronchi G., Donato M.F., Paradis V. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology. 2012;56:532–543.
    1. Fontana R.J., Bonkovsky H.L., Naishadham D., Dienstag J.L., Sterling R.K., Lok A.S. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009;7:219–226.
    1. Vergniol J., Foucher J., Castera L., Bernard P.H., Tournan R., Terrebonne E. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat. 2009;16:132–140.
    1. Patel K., Friedrich-Rust M., Lurie Y., Grigorescu M., Stanciu C., Lee C.M. FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. World J Gastroenterol. 2011;17:4581–4589.
    1. Patel K., Benhamou Y., Yoshida E.M., Kaita K.D., Zeuzem S., Torbenson M. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat. 2009;16:178–186.
    1. Poynard T., Ngo Y., Munteanu M., Thabut D., Massard J., Moussalli J. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther. 2010;15:617–631.
    1. Trivedi H.D., Patwardhan V.R., Malik R. Chronic hepatitis C infection - noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Dig Liver Dis. 2019;51:183–189.
    1. Parra-Ruiz J., Sanjuan C., Munoz-Medina L., Vinuesa D., Martinez-Perez M.A., Hernandez-Quero J. Letter: accuracy of liver stiffness measurement - a comparison of two different FibroScan devices. Aliment Pharmacol Ther. 2014;39:1434–1435.
    1. Ogawa E., Furusyo N., Toyoda K., Takeoka H., Maeda S., Hayashi J. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res. 2009;83:127–134.
    1. Hezode C., Castera L., Roudot-Thoraval F., Bouvier-Alias M., Rosa I., Roulot D. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther. 2011;34:656–663.
    1. Stasi C., Arena U., Zignego A.L., Corti G., Monti M., Triboli E. Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C. Dig Liver Dis. 2013;45:840–843.
    1. Trivedi H.D., Lin S.C., Lau D T.Y. Noninvasive assessment of fibrosis regression in hepatitis C virus sustained virologic responders. Gastroenterol Hepatol (N Y) 2017;13:587–595.
    1. D'Ambrosio R., Aghemo A., Fraquelli M., Rumi M.G., Donato M.F., Paradis V. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol. 2013;59:251–256.
    1. de Franchis R., Baveno V.I.F. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–752.
    1. Terrault N.A., Bzowej N.H., Chang K.M., Hwang J.P., Jonas M.M., Murad M.H. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261–283.
    1. Castera L. Hepatitis B: are non-invasive markers of liver fibrosis reliable? Liver Int. 2014;34(Suppl 1):91–96.
    1. Salkic N.N., Jovanovic P., Hauser G., Brcic M. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol. 2014;109:796–809.
    1. Kumar M., Sarin S.K., Hissar S., Pande C., Sakhuja P., Sharma B.C. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134:1376–1384.
    1. Marcellin P., Gane E., Buti M., Afdhal N., Sievert W., Jacobson I.M. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475.
    1. Chang T.T., Liaw Y.F., Wu S.S., Schiff E., Han K.H., Lai C.L. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010;52:886–893.
    1. Kim W.R., Berg T., Asselah T., Flisiak R., Fung S., Gordon S.C. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64:773–780.
    1. Branchi F., Conti C.B., Baccarin A., Lampertico P., Conte D., Fraquelli M. Non-invasive assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2014;20:14568–14580.
    1. Tsochatzis E.A., Gurusamy K.S., Ntaoula S., Cholongitas E., Davidson B.R., Burroughs A.K. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011;54:650–659.
    1. Verveer C., Zondervan P.E., ten Kate F.J., Hansen B.E., Janssen H.L., de Knegt R.J. Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. Liver Int. 2012;32:622–628.
    1. Fraquelli M., Rigamonti C., Casazza G., Donato M.F., Ronchi G., Conte D. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol. 2011;54:621–628.
    1. Andersen E.S., Weiland O., Leutscher P., Krarup H., Westin J., Moessner B. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scand J Gastroenterol. 2011;46:760–766.
    1. de Ledinghen V., Vergniol J., Barthe C., Foucher J., Chermak F., Le Bail B. Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus. Aliment Pharmacol Ther. 2013;37:979–988.
    1. Castera L., Friedrich-Rust M., Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1264–1281.e4.
    1. Chalasani N., Younossi Z., Lavine J.E., Charlton M., Cusi K., Rinella M. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–357.
    1. Musso G., Gambino R., Cassader M., Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617–649.
    1. Vilar-Gomez E., Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305–315.
    1. McPherson S., Hardy T., Dufour J.F., Petta S., Romero-Gomez M., Allison M. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112:740–751.
    1. Bril F., McPhaul M.J., Caulfield M.P., Castille J.M., Poynard T., Soldevila-Pico C. Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus. J Investig Med. 2019;67:303–311.
    1. Xia M.F., Yki-Jarvinen H., Bian H., Lin H.D., Yan H.M., Chang X.X. Influence of ethnicity on the accuracy of non-invasive scores predicting non-alcoholic fatty liver disease. PLoS One. 2016;11:e0160526.
    1. Daniels S.J., Leeming D.J., Eslam M., Hashem A.M., Nielsen M.J., Krag A. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 2019;69:1075–1086.
    1. Miller M.H., Walsh S.V., Atrih A., Huang J.T., Ferguson M.A., Dillon J.F. Serum proteome of nonalcoholic fatty liver disease: a multimodal approach to discovery of biomarkers of nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2014;29:1839–1847.
    1. Kamada Y., Ono M., Hyogo H., Fujii H., Sumida Y., Mori K. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology. 2015;62:1433–1443.
    1. Loomba R., Quehenberger O., Armando A., Dennis E.A. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis. J Lipid Res. 2015;56:185–192.
    1. Puri P., Wiest M.M., Cheung O., Mirshahi F., Sargeant C., Min H.K. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology. 2009;50:1827–1838.
    1. Barr J., Caballeria J., Martinez-Arranz I., Dominguez-Diez A., Alonso C., Muntane J. Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression. J Proteome Res. 2012;11:2521–2532.
    1. Zhou Y., Oresic M., Leivonen M., Gopalacharyulu P., Hyysalo J., Arola J. Noninvasive detection of nonalcoholic steatohepatitis using clinical markers and circulating levels of lipids and metabolites. Clin Gastroenterol Hepatol. 2016;14:1463–1472.e6.
    1. Grimaudo S., Pipitone R.M., Pennisi G., Celsa C., Camma C., Di Marco V. Association between PNPLA3 rs738409 C>G variant and liver-related outcomes in patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2019 [Epub ahead of print]
    1. Hardy T., Zeybel M., Day C.P., Dipper C., Masson S., McPherson S. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. Gut. 2017;66:1321–1328.
    1. Wood G.C., Chu X., Argyropoulos G., Benotti P., Rolston D., Mirshahi T. A multi-component classifier for nonalcoholic fatty liver disease (NAFLD) based on genomic, proteomic, and phenomic data domains. Sci Rep. 2017;7:43238.
    1. Szabo G., Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542–552.
    1. Wooden B., Goossens N., Hoshida Y., Friedman S.L. Using big data to discover diagnostics and therapeutics for gastrointestinal and liver diseases. Gastroenterology. 2017;152:53–67.e3.
    1. Bedossa P., Patel K. Biopsy and noninvasive methods to assess progression of nonalcoholic fatty liver disease. Gastroenterology. 2016;150:1811–1822.e4.
    1. Sanyal A.J., Friedman S.L., McCullough A.J., Dimick-Santos L. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop. Hepatology. 2015;61:1392–1405.
    1. Singh S., Allen A.M., Wang Z., Prokop L.J., Murad M.H., Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015;13 643–654.e1-9; quiz e39-40.
    1. Siddiqui M.S., Yamada G., Vuppalanchi R., Van Natta M., Loomba R., Guy C. Diagnostic accuracy of noninvasive fibrosis models to detect change in fibrosis stage. Clin Gastroenterol Hepatol. 2019;17:1877–1885.e5.
    1. Harrison S.A., Abdelmalek M.F., Caldwell S., Shiffman M.L., Diehl A.M., Ghalib R. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155:1140–1153.
    1. Harrison S.A., Rinella M.E., Abdelmalek M.F., Trotter J.F., Paredes A.H., Arnold H.L. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2018;391:1174–1185.
    1. Cheung A., Neuschwander-Tetri B.A., Kleiner D.E., Schabel E., Rinella M., Harrison S. Defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum. Hepatology. 2019;70(5):1841–1855.
    1. Helmke S., Colmenero J., Everson G.T. Noninvasive assessment of liver function. Curr Opin Gastroenterol. 2015;31:199–208.
    1. Noureddin M., Lam J., Peterson M.R., Middleton M., Hamilton G., Le T.A. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;58:1930–1940.
    1. Caussy C., Reeder S.B., Sirlin C.B., Loomba R. Noninvasive, Quantitative Assessment of liver fat by MRI-PDFF as an endpoint in NASH Trials. Hepatology. 2018;68:763–772.
    1. Permutt Z., Le T.A., Peterson M.R., Seki E., Brenner D.A., Sirlin C. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012;36:22–29.
    1. Petta S., Wong V.W., Camma C., Hiriart J.B., Wong G.L., Marra F. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology. 2017;65:1145–1155.
    1. Xiao G., Zhu S., Xiao X., Yan L., Yang J., Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486–1501.
    1. Eddowes P.J., Sasso M., Allison M., Tsochatzis E., Anstee Q.M., Sheridan D. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717–1730.
    1. Anstee Q.M., Lawitz E.J., Alkhouri N., Wong V.W., Romero-Gomez M., Okanoue T. Noninvasive tests accurately identify advanced fibrosis due to NASH: baseline data from the STELLAR trials. Hepatology. 2019;70(5):1521–1530.
    1. Hsu C., Caussy C., Imajo K., Chen J., Singh S., Kaulback K. Magnetic resonance vs transient elastography analysis of patients with nonalcoholic fatty liver disease: a systematic review and pooled analysis of individual participants. Clin Gastroenterol Hepatol. 2019;17:630–637.e8.
    1. Patel J., Bettencourt R., Cui J., Salotti J., Hooker J., Bhatt A. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2016;9:692–701.
    1. Loomba R., Lawitz E., Mantry P.S., Jayakumar S., Caldwell S.H., Arnold H. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial. Hepatology. 2018;67:549–559.
    1. Jayakumar S., Middleton M.S., Lawitz E.J., Mantry P.S., Caldwell S.H., Arnold H. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: analysis of data from a phase II trial of selonsertib. J Hepatol. 2019;70:133–141.
    1. Moreno C., Mueller S., Szabo G. Non-invasive diagnosis and biomarkers in alcohol-related liver disease. J Hepatol. 2019;70:273–283.
    1. Nguyen-Khac E., Thiele M., Voican C., Nahon P., Moreno C., Boursier J. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:614–625.
    1. Gelsi E., Dainese R., Truchi R., Marine-Barjoan E., Anty R., Autuori M. Effect of detoxification on liver stiffness assessed by Fibroscan(R) in alcoholic patients. Alcohol Clin Exp Res. 2011;35:566–570.
    1. Mueller S., Nahon P., Rausch V., Peccerella T., Silva I., Yagmur E. Caspase-cleaved keratin-18 fragments increase during alcohol withdrawal and predict liver-related death in patients with alcoholic liver disease. Hepatology. 2017;66:96–107.
    1. Thiele M., Detlefsen S., Sevelsted Moller L., Madsen B.S., Fuglsang Hansen J., Fialla A.D. Transient and 2-dimensional shear-wave elastography provide comparable assessment of alcoholic liver fibrosis and cirrhosis. Gastroenterology. 2016;150:123–133.
    1. Corpechot C. Utility of noninvasive markers of fibrosis in cholestatic liver diseases. Clin Liver Dis. 2016;20:143–158.
    1. Millonig G., Reimann F.M., Friedrich S., Fonouni H., Mehrabi A., Buchler M.W. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48:1718–1723.
    1. Wu S., Yang Z., Zhou J., Zeng N., He Z., Zhan S. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatol Int. 2019;13:91–101.
    1. Guo L., Zheng L., Hu L., Zhou H., Yu L., Liang W. Transient elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients. Med Sci Monit. 2017;23:5106–5112.
    1. Hartl J., Ehlken H., Sebode M., Peiseler M., Krech T., Zenouzi R. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. J Hepatol. 2018;68:754–763.
    1. Boursier J., de Ledinghen V., Zarski J.P., Fouchard-Hubert I., Gallois Y., Oberti F. Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive. Hepatology. 2012;55:58–67.
    1. Sebastiani G., Halfon P., Castera L., Pol S., Thomas D.L., Mangia A. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology. 2009;49:1821–1827.
    1. Srivastava A., Gailer R., Tanwar S., Trembling P., Parkes J., Rodger A. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71:371–378.
    1. Davyduke T., Tandon P., Al-Karaghouli M., Abraldes J.G., Ma M.M. Impact of Implementing a “FIB-4 First” strategy on a pathway for patients with NAFLD referred from primary care. Hepatol Commun. 2019;3:1322–1333.
    1. El-Gohary M., Moore M., Roderick P., Watkins E., Dash J., Reinson T. Local care and treatment of liver disease (LOCATE) - a cluster-randomized feasibility study to discover, assess and manage early liver disease in primary care. PLoS One. 2018;13:e0208798.
    1. Harman D.J., Ryder S.D., James M.W., Jelpke M., Ottey D.S., Wilkes E.A. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open. 2015;5:e007516.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi